DISCO Pharma Licenses Novel Cancer Surfaceome Targeted Therapies
07 Jan 2026 //
GLOBENEWSWIRE
DISCO Pharma Names Mark Manfredi CEO, Closes €36M Seed Round
11 Dec 2025 //
GLOBENEWSWIRE
DISCO launches as the surfaceome company with EUR 20 Million in Seed Financing
16 Jan 2024 //
PR NEWSWIRE

Market Place
Sourcing Support